期刊
VACCINES
卷 11, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/vaccines11050969
关键词
lung cancer; SARS-CoV-2 vaccine; immunogenicity
Compared to the general population, lung cancer patients have a higher risk of severe COVID-19 and associated mortality. Despite being prioritized for vaccination, clinical trials did not include these patients, raising concerns about vaccine efficacy and immune response. Recent investigations have focused on the humoral responses of lung cancer patients to COVID-19 vaccination.
In comparison to the general population, lung cancer patients are more likely to suffer from severe Coronavirus disease (COVID-19) and associated mortality. Considering this increased risk, and in order to prevent symptoms and severe disease, patients with lung cancer have been prioritized for COVID-19 vaccination primary and booster doses. Despite this, the pivotal clinical trials did not include these patients, which leaves open questions regarding vaccine efficacy and humoral immune response. This review outlines the findings of recent investigations into the humoral responses of lung cancer patients to COVID-19 vaccination, particularly the primary doses and first boost.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据